SCYNEXIS

SCYNEXIS, Inc. is a biotechnology company engaged in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

JERSEY CITY, N.J., June  02, 2020  (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the appointment of Jim Maffezzoli, an experienced women’s health marketing executive, as Vice President of Marketing and Sales, effective June 1, 2020. Mr. Maffezzoli will lead marketing and commercialization of SCYNEXIS’s lead clinical asset, ibrexafungerp, pending regulatory approval, for the treatment of vulvovaginal candidiasis (VVC), more commonly known as vaginal yeast infection.

SCYNEXIS Strengthens Leadership Team with Appointment of Jim Maffezzoli as Vice President of Marketing and Sales

JERSEY CITY, N.J., May  11, 2020  (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug resistant infections, today reported financial results for the quarter ended on March 31, 2020 and provided an update on recent clinical and corporate developments.

SCYNEXIS Reports First Quarter 2020 Financial Results and Provides Company Update

JERSEY CITY, N.J., May  06, 2020  (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the publication of six abstracts in the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) abstract book,  now available online .

SCYNEXIS Announces Six Abstracts Published by 30th ECCMID Highlighting the Potential Clinical Utility of Ibrexafungerp

JERSEY CITY, N.J., April  21, 2020  (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:  SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced positive top-line results for its Phase 3 VANISH-306 study investigating the safety and efficacy of oral ibrexafungerp, a novel broad-spectrum antifungal, as a treatment for women with vulvovaginal candidiasis (VVC), also known as vaginal yeast infection. With these results, ibrexafungerp has now achieved superiority over placebo with a high degree of statistical significance on key study endpoints required for regulatory approval of the VVC indication in both VANISH pivotal trials, clearing the way for the NDA submission for the treatment of VVC in the second half of 2020.

SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)

SCYNEXIS has the ability, at its discretion, to efficiently access up to $20 million of capital

SCYNEXIS and Aspire Capital Enter into $20 Million Common Stock Purchase Agreement

JERSEY CITY, N.J., April  09, 2020  (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the sale of its 6.0% Senior Convertible Notes due 2026 (the "notes") for an aggregate principal amount of $10.0 million. The notes were sold in a private offering to Puissance Capital Management pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The sale of the notes is expected to close on April 9, 2020.

SCYNEXIS Secures $10 Million in Financing through Senior Convertible Note Purchase Agreement with Puissance Capital

Scynexis: A Promising Infectious Diseases Player For 2020

As of late, it has definitely been a great time to be an investor in SCYNEXIS.

Will SCYNEXIS Continue to Surge Higher?

Scynexis (SCYX) delivered earnings and revenue surprises of 4.55% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Scynexis (SCYX) Reports Q3 Loss, Lags Revenue Estimates

Scynexis (SCYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Scynexis (SCYX) to Report a Decline in Earnings: What to Look Out for

Investors need to pay close attention to SCYNEXIS (SCYX) stock based on the movements in the options market lately.

Implied Volatility Surging for SCYNEXIS (SCYX) Stock Options

Scynexis (SCYX) delivered earnings and revenue surprises of 11.11% and -5.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Scynexis (SCYX) Reports Q2 Loss, Misses Revenue Estimates

Scynexis (SCYX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

I expect LPAD designation to be granted to both FURI and CARES trials before the end of this year.

Key Takeaways From A Follow-Up Phone Call With Scynexis CEO

Shares have risen by 25% since my January update piece.

Scynexis: Updates To Thesis, Expecting Rebound In The Near Term

Scynexis is a development stage biotechnology developing a novel antifungal, Ibrexafungerp, with a high probability of success.

Scynexis And The Fungal Economy

Scynexis (SCYX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Scynexis (SCYX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

News for SCYNEXIS Stock (SCYX)